BAJAJ BROKING

Notification
No new Notification messages
Suraksha Diagnostic IPO is Open!
Apply for the Suraksha Diagnostic IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Q2 FY'24-25 Results of Top Companies
Reliance, TCS, HDFC Bank & more: Explore key financial highlights from India's top quarterly results.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

Onyx Biotec Ltd

Pharmaceuticals

Offer Period :

13th to 18th Nov 2024

Onyx Biotec Ltd IPO Details

IPO Date 13th to 18th Nov 2024 Minimum Investment ₹122000 / 1 Lots
Listing Date 2024-11-22 Maximum Investment ₹122000 / 1 Lots
Face Value ₹10 per share Total Issue Size ₹29.34 Crores
Price ₹61 to ₹61 per share Fresh Issue ₹29.34 Crores
Lot Size 1 Lots (2000 Shares) Offer For Sale ₹ 0
Listing At NSE-SME Retail Discount ₹ 0
Employee Discount ₹0 per share    
IPO Date 13th to 18th Nov 2024
Listing Date 2024-11-22
Face Value ₹10 per share
Price ₹61 to ₹61 per share
Lot Size 1 Lots (2000 Shares)
Listing At NSE-SME
Employee Discount ₹0 per share
Minimum Investment ₹122000 / 1 Lots
Maximum Investment ₹122000 / 1 Lots
Total Issue Size ₹29.34 Crores
Fresh Issue ₹29.34 Crores
Offer For Sale
Retail Discount ₹ 0

About Onyx Biotec Limited

Founded in May 2005, Onyx Biotec Limited specializes in the production of Sterile Water for Injections and serves as a pharmaceutical contract manufacturer. The company offers an extensive range of Dry Powder Injections and Dry Syrups for both domestic and international markets. Onyx Biotec operates two manufacturing units located in Solan, Himachal Pradesh. Unit I have a daily production capacity of 638,889 units of Sterile Water for Injections. Unit II produces 40,000 units of dry powder injections and 26,667 units of dry syrup daily in a single shift. The company's clientele includes leading names like Hetero Healthcare, Mankind Pharma, Sun Pharmaceutical, Aristo Pharmaceuticals, Macleods Pharmaceuticals, Mapra Laboratories, Axa Parenterals, FDC, Zuventus Healthcare, Akums Drugs, and Reliance Life Sciences. As of May 31, 2024, Onyx Biotec's client portfolio spans over 100 Indian and multinational pharmaceutical companies. The company is ISO 9001:2015 and ISO 14001:2015 certified by ROHS Certification Private Limited and employs 175 professionals across various departments as of July 31, 2024.

Timeline

Important dates for allocation and IPO listing.

13th Nov

IPO Starts

18th Nov

IPO Ends

19th Nov

Allotment Date

20th Nov

Initiation of Refund

20th Nov

Credit of Shares to Demat Account

22nd Nov

IPO Listing Date

Shareholder Pattern

  Pre-Issue Post-Issue
Promoter Group 88.6 65.1
Public Group 11.4 34.9

Onyx Biotec Ltd IPO Reservation

QIB Shares Offered 912000(18.96%)
NII (HNI) Shares Offered 688000(14.3%)
Retail Shares Offered 1600000(33.26%)
Anchor Investor Shares Offered 1366000(28.4%)
Total Shares Offered 4810000
Total Shares With Anchor Investor 4810000

IPO Lot Size

ApplicationLotsSharesAmount
Retail (Min)---
Retail (Max)---
S-HNI (Min)---
S-HNI (Max)---

Onyx Biotec Ltd IPO Registrar

Mas Services Limited
Phone Number 91 112 6387281/83,114 1320335
Email Id investor@masserv.com
Our Website www.masserv.com

Onyx Biotec Ltd IPO Lead Manager

1. Horizon Management Pvt Ltd

Explore IPOs


Explore comprehensive IPO details for every IPO. Access essential information such as listing price, listing date, issue price, lot size, issue size, minimum investment, and IPO timeline. Gain insights into the company's background, strengths, and potential risks. Track the subscription status and delve into the financials of the company, empowering yourself with crucial data for informed investment decisions. Stay ahead in the dynamic IPO market by staying informed on upcoming, ongoing, and past IPOs. 
 

Stay ahead in the ever-evolving IPO landscape with our comprehensive platform. We offer a holistic resource, ensuring you not only access essential details but also gain valuable insights into market trends. Navigate confidently, armed with intricate analyses, expert opinions, and real-time updates. Whether you're a seasoned investor or a novice, our user-friendly interface and extensive information empower you to make well-informed decisions. Experience the convenience of having a dedicated space where you can delve into the intricacies of IPOs, enabling a strategic and calculated approach to the dynamic stock market. 

Onyx Biotec Ltd IPO Subscription LIVE Status

Category No. of shares offered No. of shares bid No. of subscribed
QIB 9,12,000 0 0.0
Non Institutional Investors 9,32,000 1,01,94,000 1,096.0
Retail Individual Investors (RIIs) 16,00,000 3,66,72,000 18,336.0
Total 34,44,000 4,68,66,000 19,432.0

Strength of Onyx Biotec Ltd

1. One of the prominent contract manufacturers in sterile manufacturing.

2. Quality Assurance and Quality Control of our products.

3. Strong, cordial & long-term relationship with our Marque Clientele.

4. Cost effective production and timely fulfilment of orders.

5. Well experienced management team with proven project management and implementation skills.

Risks Involved

1. Its manufacturing units are concentrated in Solan, Himachal Pradesh, and the company is exposed to risks originating from economic, regulatory, political and other changes in this region, including natural disasters, which could adversely affect its business, results of operations and financial condition.

2. Any slowdown or shutdown in its manufacturing operations could have an adverse effect on its business, results of operations, financial condition and cash flows.

3. Any manufacturing or quality control concerns or its inability to deliver products on a timely basis, or at all, could result in the cancellation of purchase orders, breaches of relevant agreements, and termination of agreements by its clients and distributors, which could have an adverse effect on its business, results of operations, financial condition and cash flows.

4. Its manufacturing units are subject to periodic inspections and audits by regulatory authorities and clients. The company may be subject to regulatory action which may damage its reputation leading to an adverse effect on its business, results of operations, financial condition and cash flows.

5. The company relies on domestic and international third-party suppliers for the supply of raw materials and any delay, interruption or reduction in such supply could adversely affect its business, results of operations, financial condition and cash flows.

6. Its business is dependent on sale of products to a limited number of clients for a significant portion of its revenues. The loss of one or more such clients or the deterioration of their financial condition or prospects could adversely affect its business, results of operations and financial condition.

7. The Company is reliant on the demand from the pharmaceutical industry. Any downturn in the pharmaceutical industry or an inability to increase or effectively manage its sales could have an adverse impact on the Company's business and results of operations.

8. The commercial success of its products depends to a large extent on the success of the products of its customers. If the demand for the products of the company's customers declines, it could have a material adverse effect on its business, financial condition and results of operations.

9. Its may faces several risks associated with the proposed expansion of the company's manufacturing facilities, which could hamper its growth, prospects, cash flows and business and financial condition.

10. Its cannot assure you that the proposed expansion of the company's manufacturing units will become operational as scheduled, or at all, or operates as efficiently as planned. If the company is unable to commission its new facilities in a timely manner or without cost overruns, it may adversely affect its business, results of operations and financial condition.

Industry Outlook of Onyx Biotec IPO

- The Indian pharmaceutical market is set for exponential growth, with projections estimating it to reach US$ 130 billion by 2030 and a staggering US$ 450 billion by 2047. This growth trajectory is fueled by increasing demand for innovative therapies and a strong domestic industry foundation.

 

- India ranks 3rd globally in pharmaceutical production by volume and 14th by value, highlighting its robust manufacturing capacity and global influence in drug supply.

 

- The country boasts a well-established network comprising 3,000 drug companies and approximately 10,500 manufacturing units, making it a significant player in the global pharmaceutical landscape.

 

- Exports contribute significantly to India’s pharmaceutical industry, with exports valued at US$ 27.82 billion in FY24. The industry accounts for 20% of global generic drug exports, emphasizing its crucial role in the international market.

 

- Between FY18 and FY23, the industry experienced a compound annual growth rate (CAGR) of 6-8%, supported by an 8% increase in exports and 6% growth in the domestic market.

Why should you invest in

-

Financials

Particulars For the financial year ending (in ₹ million)
 
Total Assets
Total Liabilities
Total Expenses
Total Revenue 
Profit After Tax
EBITDA
Adjusted EBITDA

Onyx Biotec Ltd IPO Listing Details

Listing Date BSE Script Code NSE Symbol ISIN Final Issue Price
2024-11-22 93585 ONYX
INE0WVU01018
₹61 per share

Listing Day Trading Information

Price Details BSE NSE
Final Issue Price ₹61 ₹61
Open ₹0 ₹54.05
Low ₹0 ₹51.45
High ₹0 ₹56.75
Low ₹0 ₹51.45

Interested in more opportunities? Check out our Upcoming IPO section for new listings and don’t forget to check your IPO allotment status for Onyx Biotec Ltd IPO

 

Frequently Asked Questions

What is Onyx Biotec Ltd IPO?

Answer Field

Onyx Biotec Ltd IPO is a SME IPO of 48,10,000 equity shares of a face value of ₹10 aggregating up to ₹29.34 Crores. The issue is priced at ₹61 to ₹61 per share. The minimum order quantity is 2000 Shares. The IPO opens on November 13, 2024, and closes on November 18, 2024. Mas Services Limited is the registrar for the IPO. The shares are proposed to be listed on NSE-SME.

When Onyx Biotec Ltd IPO will open?

Answer Field

The Onyx Biotec Ltd IPO opens on November 13, 2024 and closes on November 18, 2024.

What is the lot size of Onyx Biotec Ltd?

Answer Field

Onyx Biotec Ltd lot size is 2000 shares, and the minimum amount required is ₹1,22,000.

How to apply for Onyx Biotec Ltd IPO?

Answer Field

You can apply in Onyx Biotec Ltd IPO online using either UPI or ASBA as payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO application is offered by brokers who don't offer banking services. To apply for an IPO:

• Login to Bajaj Broking account App/Website & click on IPO

• Enter the number of lots and price at which you wish to apply.

• Enter your UPI ID and click on submit. With this, your bid will be placed with the exchange.

• You will receive a mandate notification to block funds in your UPI app.

• Approve the mandate request on your UPI and funds will be blocked.

When is Onyx Biotec Ltd IPO allotment?

Answer Field

The finalization of Basis of Allotment for Onyx Biotec Ltd IPO will be done on November 19, 2024, and the allotted shares will be credited to your demat account by November 20, 2024.

When is Onyx Biotec Ltd IPO listing date?

Answer Field

The Onyx Biotec Ltd listing date is November 22, 2024.

Who is the registrar of Onyx Biotec Ltd IPO?

Answer Field

The registrar of Onyx Biotec Ltd IPO is Mas Services Limited

Which company is the book-running lead manager of the IPO?

Answer Field

Horizon Management Pvt Ltd will be the book-running lead manager of this IPO.

What is the fresh issue of Onyx Biotec Ltd IPO?

Answer Field

The fresh issue size is ₹29.34 Crores equity shares.

What minimum lot size can retail subscribers subscribe to Onyx Biotec Ltd?

Answer Field

Retail investors can subscribe to a minimum of one lot, 2000 shares and ₹1,22,000 amount.

How can I approve the UPI mandate request for Onyx Biotec Ltd IPO?

Answer Field

To apply for Onyx Biotec Ltd IPO, you need to log in to your demat account to complete the bidding process. Then, approve the payment mandate on your UPI app.

What is the price range of Onyx Biotec Ltd?

Answer Field

The price of each Onyx Biotec Ltd share will be ranging in between ₹61 to ₹61 per share.

What is the cut-off time for the UPI mandate for Onyx Biotec Ltd IPO?

Answer Field

The cut-off time for the UPI mandate confirmation is 5:00 PM, November 18, 2024.

No results found

Browse IPOs

upcoming-radio
  • IPO Name
  • Bidding Dates
  • Price range
  • IPO Size
  • Lorem Ipsum
current-radio
  • IPO Name
  • Bidding Dates
  • Price range
  • IPO Size
  • Lorem Ipsum
  • SURAKSHA DIAGNOSTIC LIMITEDMainboard IPO

  • Bidding Dates

    29th Nov 2024 - 12th Dec 2024

  • Price Range

    ₹420.0 - 441.0

  • IPO Size

    ₹8,46,25,00,000

  • Apply Now
  • GANESH INFRAWORLD LIMITEDSME IPO

  • Bidding Dates

    29th Nov 2024 - 12th Dec 2024

  • Price Range

    ₹78.0 - 83.0

  • IPO Size

    ₹98,57,00,000

  • Apply Now
closed-radio
  • IPO Name
  • Bidding Dates
  • Price range
  • IPO Size
  • Lorem Ipsum
  • SWIGGY LIMITEDMainboard IPO

  • Bidding Dates

    6th Nov 2024 - 11th Nov 2024

  • Price Range

    ₹371.0 - 390.0

  • IPO Size

    ₹1,13,27,43,00,000

  • Invest Now
performance-radio
  • IPO Name
  • ISSUE PRICE
  • LISTING DAY CLOSE
  • LISTING DAY(GAIN/LOSS)
  • Lorem Ipsum
  • ONYX BIOTEC LIMITEDSME IPO

  • Issue Price

    61.00

  • Listing Day Close

    56.75

  • Listing Day (Gain/Loss)

    -6.56

  • SWIGGY LIMITEDMainboard IPO

  • Issue Price

    390.00

  • Listing Day Close

    455.95

  • Listing Day (Gain/Loss)

    16.92

  • DANISH POWER LIMITEDSME IPO

  • Issue Price

    380.00

  • Listing Day Close

    598.50

  • Listing Day (Gain/Loss)

    57.63

We have something for everyone

Explore more Investment options

Stocks

Secure and enhance your financial future today

investment-card-icon

IPOs

Your gateway to future financial opportunities

investment-card-icon

MTF

Explore Buy Now Pay Later and boost your capital by up to 4x  

investment-card-icon

US Stocks

Discover opportunities to invest in elite FAANG stocks

investment-card-icon

Related Articles

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

8 Lacs + Users

icon-with-text

4.8+ App Rating

icon-with-text

4 Languages

icon-with-text

₹5000+ Cr MTF Book

icon-with-text